Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system
Ke Ma1
Xiao-Xiao Han2
Xiao-Ming Yang2
Song-Lin Zhou2
1.College of Life Science,Nantong University,Nantong,Jiangsu Province,China2.Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education,Jiangsu Clinical Medicine Center of Tissue Engineering and Nerve Injury Repair,Co-Innovation Center of Neuroregeneration,Nantong University,Nantong,Jiangsu Province,China
摘要：Neurological diseases such as stroke, Alzheimer's disease, Parkinson's disease, and Huntington's disease are among the intractable diseases for which appropriate drugs and treatments are lacking. Proteolysis targeting chimera (PROTAC) technology is a novel strategy to solve this problem. PROTAC technology uses the ubiquitin-protease system to eliminate mutated, denatured, and harmful proteins in cells. It can be reused, and utilizes the protein destruction mechanism of the cells, thus making up for the deficiencies of traditional protein degradation methods. It can effectively target and degrade proteins, including proteins that are difficult to identify and bind. Therefore, it has extremely important implications for drug development and the treatment of neurological diseases. At present, the targeted degradation of mutant BTK, mHTT, Tau, EGFR, and other proteins using PROTAC technology is gaining attention. It is expected that corresponding treatment of nervous system diseases can be achieved. This review first focuses on the recent developments in PROTAC technology in terms of protein degradation, drug production, and treatment of central nervous system diseases, and then discusses its limitations. This review will provide a brief overview of the recent application of PROTAC technology in the treatment of central nervous system diseases.
机标关键词：
论文发表日期：2021-10-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：6( 1944-1949 )
英文信息